GODMET PG2
In diabetic patient uncontrolled on dual therapy
- Increase insulin sensitivity and has beneficial effects on lipid levels
- Decrease the triglycerides and increase HDL cholesterol
- Highly appriciable in diabetic patients with CKD patients
- The recent NICE clinical guidelines endorses pioglitazone based therapy over DPP4 inhibitors